The GLP-1 Economy
11m | Sep 17, 2026GLP-1 medicines and tirzepatide can produce substantial average weight loss and improve selected cardiometabolic outcomes, but their recurring costs, side effects, access barriers and uncertain long-term savings complicate the case for patients, insurers, employers and public programs. Factolio examines the medical, economic and political consequences.
Read the full discussion and sources:

factolio
Loading...